Infanrix Vaccine Description
Infanrix is a vaccine indicated for active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children aged 6 weeks.
Infanrix active ingredients are non-infectious substances from tetanus, diphtheria bacteria, and purified proteins of pertussis bacteria. Each 0.5 mL dose contains: 30 IU (25 Lf U) of diphtheria toxoid.
Infanrix Vaccine Indication
Infanrix is a vaccine indicated for active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children 6 weeks to 7 years of age (prior to seventh birthday).
Infanrix Vaccine Dosage
Infanrix is approved for intramuscular administration in infants and children 6 weeks to 7 years of age (prior to the seventh birthday) as a 5-dose series
A primary immunization course of 3 doses administered at 2, 4, and 6 months of age (at intervals of 4 to 8 weeks). The first dose may be given as early as 6 weeks of age
Followed by 2 booster doses, administered at 15 to 20 months of age and at 4 to 6 years of age
Preferred administration site:
Anterolateral aspect of the thigh for most infants younger than 12 months of age
Deltoid muscle of the upper arm for most children 12 months of age to 7 years of age
Infanrix Vaccine News
October 31, 2019 - GSK Korea announced its newly launched Infanrix IPV-Hib, a quintuplet vaccine that covers diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b (Hib). The company hopes that by adding efficiency to the excellence of the existing Infanrix brand, it can become a vaccine that leads to the prevention of disease for infants and toddlers, said Professor Lee Jin of the Department of Pediatrics at Hanil Hospital.
Infanrix Vaccine Clinical Trials
Infanrix has been tested in over 140 clinical trials. They can be found at this link.